We applied an innovative and highly sensitive Proximity Extension Assay (PEA) for comprehensive profiling of ~1000 proteins in the plasma of 55 metastatic melanoma patients that received anti-PD-1 treatment whereas, 18 patients were previously treated with anti-CTLA-4 while 37 received anti-PD-1 monotherapy. Here, CTLA4 is linked to metastatic melanoma.